Q-omics provides the consensus-scored RNY1P16 profile across patient tissues and cancer cell-line models. RNY1P16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RNY1P16 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, RNY1P16 RNA expression shows 15,660 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, LUAD, and UVM as cancer lineages where RNY1P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY1P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY1P16 survival associations across molecular data types. RNY1P16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY1P16 RNA expression–survival associations across cancer types. High RNY1P16 expression shows unfavorable associations in UVM, KICH, CHOL and COAD, but favorable associations in BRCA and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RNY1P16 RNA expression.
This table summarizes RNY1P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNY1P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY1P16 shows lower tumor expression in LUAD and higher tumor expression in THCA and LIHC. The LUAD box plot shows higher RNY1P16 RNA expression in normal versus tumor tissue (log2 FC = −0.848, t-test p = .013).
This table shows molecular features associated with RNY1P16 in patient tissues and cancer cell lines. In patient samples, RNY1P16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
